ClinicalTrials.gg
RecruitingNCT07600476Updated Nov 18, 2026

A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors

A Phase 1 interventional study of KUP-101A in Cutaneous Melanoma, Mucosal Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Kupando GmbH. Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Kupando GmbH · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 18, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.

Planned enrollment
213th of 249
21 · median 162
Started
2026
with 7 others
Phase 1
36 of 284
2 open now
Primary completion
2028-12
later than 59 of 69 live
Registered
280th of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 213th largest by planned enrollment of the 249 interventional ones that give a count, is one of 8 that started in 2026, is one of 36 in phase 1, reaches primary completion later than 59 of the 69 other live ones, and was the 280th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.

03

Conditions studied

  • Cutaneous Melanoma
  • Mucosal Melanoma
  • Cutaneous Squamous Cell Carcinoma (CSCC)
  • Merkel Cell Carcinoma of Skin
  • Basal Cell Carcinoma of Skin

Keywords

  • TLR4 agonist
  • TLR7 agonist
  • TLR4/7 agonist
  • skin cancer
  • innate immunity
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed cancer with evidence of advanced disease for which no other standard treatment is available
  • Performance status of 0 to 2
  • Adequate hematological, renal, and hepatic organ function

Exclusion criteria

Exclusion Criteria:

  • Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.
  • Known additional that is progressing or requires active treatment
  • Diagnosis of immunodeficiency
  • Active disease not caused by prior anticancer treatment that required systemic treatment in the past 2 years
  • Active autoimmune disease caused by prior anticancer treatment, unless currently controlled by replacement therapy only.
  • Any kind of leukemia
  • Previously received an organ transplant (other than corneal transplants) or hematopoietic stem cell transplantation
  • Known active central nervous system and/or carcinomatous meningitis
  • Cerebral vascular event within 6 months before Screening
  • Unstable cardiopulmonary status defined by uncontrolled congestive heart failure of Grade III or IV, unstable angina, or myocardial infarction within 6 months before Screening
  • High grade ocular disease such as uncontrolled glaucoma
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Dose level 1

    Drug: KUP-101A

  • Experimental
    Dose level 2

    Drug: KUP-101A

  • Experimental
    Dose level 3

    Drug: KUP-101A

  • Experimental
    Dose level 4

    Drug: KUP-101A

  • Experimental
    Dose level 5

    Drug: KUP-101A

  • Experimental
    Dose level 6

    Drug: KUP-101A

  • Experimental
    Dose level 7

    Drug: KUP-101A

Interventions

  • DrugKUP-101A

    Intravenous infusion of KUP-101A

06

What researchers measure

Primary outcomes

  1. Proportion of patients with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and related TEAEs

    Time frame: From enrollment until three months after last dose administration

  2. Proportion of patients with dose-limiting toxicities (DLTs)

    Time frame: From start of treatment until one week after last dose administration.

  3. Incidence of laboratory abnormalities, based on hematology, clinical chemistry, and urinalysis test results

    Time frame: From enrollment until three months after last dose administration

  4. Incidence of abnormal clinical findings in 12-lead ECG parameters and vital signs

    Time frame: From enrollment until three months after last dose administration

Secondary outcomes

  1. Area Under the Concentration time Curve from Time 0 Extrapolated to Infinity

    Time frame: up to 3 weeks

  2. Maximum Observed Concentration

    Time frame: up to 3 weeks

  3. Time of the maximum observed concentration

    Time frame: up to 3 weeks

  4. Apparent terminal elimination half-life

    Time frame: up to 3 weeks

  5. Change from baseline in cytokine levels

    Time frame: From enrollment until three months after last dose administration

07

Study locations

4 of 4 sites recruiting
  • Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
    Munich, Bavaria 80337, Germany
    Recruiting
  • Universitätsklinikum Würzburg
    Würzburg, Bavaria 97080, Germany
    Recruiting
  • Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie
    Marburg, Hesse 35043, Germany
    Recruiting
  • Fachklinik Hornheide
    Münster, North Rhine-Westphalia 48157, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 226 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's planned 29 months is below that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 20, 2026
StartActual
Jul 3, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie · Marburg, Germany
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added
    Show site
    • Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie · Marburg, Germany
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07600476
Lead sponsor
Kupando GmbH
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Jul 3, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Clinical Operations
Contact
clinicaltrials@kupando.com
+49 30 52 00 58 60 20

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion